Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Poxel to Present at Upcoming Investor Conferences


POXEL S.A. (Euronext ? POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that company management will present at two upcoming investor conferences in November:

William Blair Boston Innovation Day
Date:
November 12, 2019
Time: 9:00 am EST
Location: 200 Claredon Street, Boston, MA

Jefferies 2019 London Healthcare Conference
Date:
November 20, 2019
Time: 1:20 pm GMT
Location: Waldorf Hilton, London, UK

The Jefferies 2019 London Healthcare Conference presentation will be live streamed via webcast.

To access the webcast, please visit: http://wsw.com/webcast/jeff123/poxel.pa/. The webcast replay will remain available for 90 days following the live presentation.

About Poxel SA

Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel's first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin's development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com.


These press releases may also interest you

at 22:30
Canadian digital healthcare portal Ask The Doctor has launched a toll-free number for anyone around the world to call who are concerned about the Coronavirus. "It is our duty and it is our responsibility to help people around the world as we are...

at 14:05
Accumen Inc., the leader in healthcare performance within ancillary services, today announced that it is partnering with AABB and The Joint Commission to provide a complimentary series of Patient Blood Management (PBM) Certification webinars focusing...

at 11:00
February 17, 2020 The itinerary of events includes: Vancouver, British Columbia 8:00a.m. PST: Minister Hajdu, The Honourable Adrian Dix, British Columbia Minister of Health, and His Worship Kennedy Stewart, Mayor of Vancouver, will host a roundtable...

at 08:00
Chad Price, the CEO of Mako Medical, announced this week that Mako Medical Laboratories is launching a new DNA test focused on Nutrition. "This is a first step in helping people understand exactly what foods they should eat so they can optimize...

at 08:00
In Partnership with the Smiles for Everyone Foundation, Bright Now!® Dental will provide free dental services at its Kennewick, WA office. A limited number of appointments are available, but there is plenty of room for walk-ins if individuals are...

15 fév 2020
Further to my previous statements, as Chief Public Health Officer, I have assessed additional individuals in quarantine at Canadian Forces Base (CFB) Trenton pursuant to an Emergency Order under the Quarantine Act and determined that they do not pose...



News published on 7 november 2019 at 11:50 and distributed by: